- Latest news▼
-
12:16, April 19 Scientists grow human mini-lungs in lab
-
10:23, April 19 JAMA Oncology: Urine test can help rule out high-grade prostate cancer with almost 100% accuracy, study shows
-
18:00, April 18 Daily Mail: Elderly woman in China gets infected with brain-eating amoeba
-
14:19, April 18 Obesity: exercising before breakfast helps you lose weight faster
-
10:42, April 18 The Conversation: childhood trauma can cause pathological hoarding
-
08:37, April 18 Daily Mail: Satiating food reduces cravings for sweets, nutritionist says
-
18:22, April 17 First Armenian-German Conference entitled “Heart Failure Spring School”
-
08:38, April 17 Why do kids usually recover from COVID-19 more easily than adults?
-
14:37, April 16 Daily Mail: intermittent fasting is not suitable for children and women before their periods
-
16:41, April 15 Cell: in carriers of defective BRCA2 gene, sugar consumption increases cancer risk
-
15:04, April 15 305 cases of measles recorded in Armenia so far in 2024
-
14:38, April 15 Food and Environmental Virology: tea contributes to effective coronavirus control
-
12:41, April 15 Daily Mail: vitamin A, B3 and E supplements can be dangerous
-
10:56, April 15 Diabetes Care: evening physical activity is good for the heart
-
08:27, April 15 Women are more susceptible to blood loss and death during bypass surgery than men, researchers say
All materials
Lilly, Boehringer copy of Sanofi's insulin gets EU approval
Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus.
The treatment, to be manufactured by Lilly, comprises a type of basal insulin, intended to provide long-lasting blood sugar control between meals and at night, Reuters reported.
The therapy received a positive recommendation from the European Medicine Agency in June.
The approval is for a so-called biosimilar version of Lantus, which generates annual sales of about $8 billion. Biosimilar medicines are copies of biotech drugs that promise to cut the cost of treatment.
Lantus currently dominates the market, out-selling a rival treatment Levemir from Denmark's Novo Nordisk.
Follow NEWS.am Medicine on Facebook and Twitter
- Video
- Event calendar
- Archive
- Most read
month
week
day
- WHO: Nigeria pioneers revolutionary meningitis vaccine 1191
- One-third of women experience menstruation-related migraines, most often during premenopause - study 1190
- Daily Mail: vitamin A, B3 and E supplements can be dangerous 1089
- Food and Environmental Virology: tea contributes to effective coronavirus control 1082
- Cell: in carriers of defective BRCA2 gene, sugar consumption increases cancer risk 1053
- 305 cases of measles recorded in Armenia so far in 2024 1047
- Women are more susceptible to blood loss and death during bypass surgery than men, researchers say 975
- Diabetes Care: evening physical activity is good for the heart 931
- Daily Mail: intermittent fasting is not suitable for children and women before their periods 877
- First Armenian-German Conference entitled “Heart Failure Spring School” 645
- Obesity: exercising before breakfast helps you lose weight faster 546
- Why do kids usually recover from COVID-19 more easily than adults? 545
- The Conversation: childhood trauma can cause pathological hoarding 543
- Daily Mail: Elderly woman in China gets infected with brain-eating amoeba 537
- Daily Mail: Satiating food reduces cravings for sweets, nutritionist says 509
- Find us on Facebook
- Poll